For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250929:nRSc0752Ba&default-theme=true
RNS Number : 0752B Angle PLC 29 September 2025
For immediate release 29 September 2025
ANGLE plc ("the Company")
CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma Patients
GBM CTC isolation only possible with Parsortix label-free methodology
Data presented at the 7(th) ACTC meeting
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the presentation of
new data from a proof-of-concept study in glioblastoma at the 7th Advances in
Circulating Tumour Cells (ACTC) meeting, held 24-27 September 2025 in
Thessaloniki, Greece.
The poster entitled 'Detection of circulating tumour cells from glioblastoma
patients' blood samples' reports on data from 15 newly diagnosed,
treatment-naïve glioblastoma (GBM) patients whose blood was processed using
the Parsortix(®) system and CellKeep™ slides. This approach has the
potential to allow for minimally invasive, repeatable monitoring in patients
with GBM.
Key findings:
· CTCs were detected in 60% of patients and CTC clusters, which are
known to have high metastatic potential, were observed in 78% of CTC-positive
patients. This is particularly significant given that ctDNA is observed in
less than 10% of glioma patients possibly due to failure to cross the
blood-brain barrier(1)
· All CTCs detected exhibited a mesenchymal phenotype, consistent
with the biology of GBM, which would not be detectable using traditional CTC
technologies that rely on cell surface markers to isolate CTCs
· Extracellular vesicles (EVs) were observed in 73% of subjects,
further supporting the potential of liquid biopsy for dynamic monitoring in
GBM
· The ability to harvest and analyse CTCs and EVs from a single
blood sample opens new avenues for a multi-analyte, minimally invasive,
real-time assessment of tumour biology, disease progression, and response to
therapy in GBM patients
ANGLE's Chief Scientific Officer, Karen Miller, commented:
"We are delighted to present our first data in GBM at the ACTC 2025
conference. These results demonstrate the capability of the Parsortix
label-free system to capture and characterise CTCs in GBM where ctDNA
approaches have struggled. This creates the opportunity to start monitoring
GBM patients using proteomic and molecular biomarkers during their treatment,
as well as support pharma companies developing new drugs for this cancer."
The poster is available on ANGLE's website:
https://angleplc.com/resources/posters/
(https://angleplc.com/resources/posters/)
1. Bettegowda C. et al. Detection of circulating tumor DNA in early- and
late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24.
doi: 10.1126/scitranslmed.3007094
For further information:
ANGLE plc +44 (0) 1483 343434
Jan Groen (Chair of the Board)
Cavendish (NOMAD and Broker)
Geoff Nash / Isaac Hooper +44 (0) 20 7220 0563
Sunila de Silva (Corporate Broking)
Nigel Birks - Life Science Specialist Sales
FTI Consulting
Simon Conway, Ciara Martin, Sam Purewal +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis. The
CellKeep slide is ANGLE's patented CTC harvesting technology, for high
quality, reproducible and robust imaging of CTCs.
ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.
Over 115 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)
Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:
The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer. The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood. The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays. The end
user is responsible for the validation of any downstream assay. The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.
About Glioblastoma
GBM is the most common and aggressive malignant brain tumour in adults, with
an incidence of around 3-5 cases per 100,000 people annually worldwide.
Prognosis remains poor despite treatment: median overall survival is typically
12-15 months and five-year survival rates are below 10%. Current standard of
care combines surgery, radiotherapy and the chemotherapeutic agent
temozolomide, with limited benefit derived from other approved drugs. There is
a high unmet clinical need to drive significant global research into novel
treatment approaches. CTC isolation and analysis has the potential to
transform targeted treatment selection, disease monitoring and drug
development in this high-need indication.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAEQLFLEKLXBBD